News | March 11, 2009

Leading Middle East Cancer Hospital Acquires Varian’s RapidArc

March 11, 2009 - One of the leading cancer centers in the Middle East has acquired two advanced radiotherapy devices from Varian Medical Systems equipped with RapidArc technology for fast and precise treatments.

Al Amal Hospital in Doha, Qatar, is replacing four-year-old linear accelerators with Trilogy and Clinac iX devices, aiming to provide patients with more modern and efficient treatments.

The new equipment, ordered in February and scheduled to be installed in May, will enable clinicians in Qatar's only radiation therapy center to begin treatments using RapidArc, Varian's latest technology for delivering image-guided intensity-modulated radiotherapy (IMRT) with greater precision and up to eight times faster than is possible with conventional IMRT.

Dr. Noora Mohammed Al-Hammadi, head of the department of radiation oncology, said, "Evidence suggests that RapidArc will revolutionize the way IMRT is delivered and potentially improve patient outcomes. Faster treatment that more closely conform radiation doses to the size, shape and location of the tumor are always desirable in radiotherapy, for both machine throughput as well as patient outcomes. We are very excited about the potential of RapidArc."

RapidArc delivers a precise and efficient treatment in single or multiple arcs of the medical linear accelerator around the patient. Varian's Clinac and Trilogy accelerators can target beams at a tumor while continuously rotating around the patient. Conventional IMRT treatments are slower for radiotherapists because they use many fixed angle beams rather than a continuous rotational beam.

For more information: www.varian.com

Related Content

​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
UZ Leuven Treats First European Patient on Varian Halcyon Cancer Treatment System
News | Intensity Modulated Radiation Therapy (IMRT) | October 25, 2017
Varian recently announced an 80-year-old male with head and neck cancer became the first patient in Europe to be...
Varian Receives FDA 510k Clearance for Halcyon Treatment System
Technology | Intensity Modulated Radiation Therapy (IMRT) | July 05, 2017
Varian Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Halcyon system,...
First New York Metropolitan Hospital Treats Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | July 03, 2017
Accuray Inc. and Montefiore Einstein Center for Cancer Care (MECCC), part of the Montefiore Health System (MHS),...
IUCT Oncopole Installs First Radixact Radiotherapy System in France
News | Intensity Modulated Radiation Therapy (IMRT) | June 20, 2017
Accuray Inc. announced that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) in Toulouse, France,...
cervical and endometrial cancer, IMRT, intensity modulated radiation therapy, side effects, ASTRO 2016 study
News | Intensity Modulated Radiation Therapy (IMRT) | September 29, 2016
Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience...
non-small cell lung cancer, NSCLC, IMRT, toxicity, intensity modulated radiation therapy, 3-D CRT, ASTRO 2015
News | Lung Cancer | October 28, 2015
October 28, 2015 — An analysis of an international, cooperative-led trial of patients with locally advanced non-small
pediatric ependymoma patients, immediate post-surgical radiation therapy, Children's Oncology Group ACNS0121 trial, ASTRO 2015
News | Radiation Therapy | October 22, 2015
Outcomes for pediatric patients as young as 12 months with ependymoma who are treated with immediate post-operative...
Overlay Init